Live Breaking News & Updates on Decision Diagnostics Corp

Stay updated with breaking news from Decision diagnostics corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SEC.gov | SEC Charges Biotech Company and CEO With Fraud Concerning COVID-19 Blood Testing Device


FOR IMMEDIATE RELEASE
Washington D.C., Dec. 18, 2020
The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics securities on April 23, 2020.
The SEC s complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics Covid- ....

New York , United States , District Of Columbia , Stephanie Avakian , Hanel Kim , James Carlson , Keith Berman , Tom Bednar , Jeff Leasure , Carlisle Perkins , Margareta Cain , David Misler , Lesley Atkins , Coronavirus Steering Committee , Decision Diagnostics Corp , Financial Industry Regulatory Authority , Division Of Enforcement , Us District Court , Microcap Fraud Task , Office Of Market Intelligence , Exchange Commission , Department Of Justice Market Integrity , Decision Diagnostics , Decision Diagnostic , Associate Director , Southern District ,

SEC sues California biotech company for misleading investors...


NEW YORK, Dec 17 (Reuters) - The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute.
In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements between March and June about what he claimed was his company s blood testing kit, and its efforts to obtain Food and Drug Administration approval for its emergency use.
The SEC said all the California-based company had at the time was a theoretical concept that had not yet materialized into a product, and that Berman s misstatements led to surges in Decision Diagnostics stock price and trading volume. ....

New York , United States , Keith Berman , Jonathan Stempel , Exchange Commission , Decision Diagnostics Corp , Drug Administration , Chief Executive Keith Berman , Decision Diagnostic , Will Dunham , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , கேய்ட் பெர்மன் , ஜொனாதன் ஸ்டெம்பல் , பரிமாற்றம் தரகு , முடிவு பரிசோதனை கார்ப் , தலைமை நிர்வாகி கேய்ட் பெர்மன் , முடிவு கண்டறியும் , விருப்பம் டன்ஹாம் ,